[
  {
    "ts": null,
    "headline": "Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "summary": "In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=6698b37fdec9deb744e3642acb3160a331b1c327e81cc50b1772a5fd3ac3b040",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752875104,
      "headline": "Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know",
      "id": 136011907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=6698b37fdec9deb744e3642acb3160a331b1c327e81cc50b1772a5fd3ac3b040"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating",
    "summary": "Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on Merck & Co. (NYSE: MRK) to $141 from $138 while maintaining a Buy rating, citing increased conviction in the company’s recent acquisition of Verona Pharma. The firm’s analysts see the $10 billion deal […]",
    "url": "https://finnhub.io/api/news?id=960fc2744ec014fd02dde9b04fb7cebb2d39e07aa268266975c0b66aa736fd70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752864354,
      "headline": "Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating",
      "id": 136011908,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on Merck & Co. (NYSE: MRK) to $141 from $138 while maintaining a Buy rating, citing increased conviction in the company’s recent acquisition of Verona Pharma. The firm’s analysts see the $10 billion deal […]",
      "url": "https://finnhub.io/api/news?id=960fc2744ec014fd02dde9b04fb7cebb2d39e07aa268266975c0b66aa736fd70"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 130-point fall led by losses in shares of 3M, American Express",
    "summary": "Dow's 130-point fall led by losses in shares of 3M, American Express",
    "url": "https://finnhub.io/api/news?id=e9a6826edb987f8f6b4e1cae7d8759875480047d254e2a6f9c3cb4b15c46897b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752854160,
      "headline": "Dow's 130-point fall led by losses in shares of 3M, American Express",
      "id": 136041825,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 130-point fall led by losses in shares of 3M, American Express",
      "url": "https://finnhub.io/api/news?id=e9a6826edb987f8f6b4e1cae7d8759875480047d254e2a6f9c3cb4b15c46897b"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN",
    "summary": "– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN)",
    "url": "https://finnhub.io/api/news?id=1c92972879b9bef5c3e101ee6293729d8b5529f0302b89b1f60f4908de2ee9ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752852600,
      "headline": "European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN",
      "id": 136005600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN)",
      "url": "https://finnhub.io/api/news?id=1c92972879b9bef5c3e101ee6293729d8b5529f0302b89b1f60f4908de2ee9ad"
    }
  },
  {
    "ts": null,
    "headline": "J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?",
    "summary": "JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.",
    "url": "https://finnhub.io/api/news?id=d2a9086031965b4ec27f20fd36ef39587dbf3fb10ab06cf42c7000555d686142",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752851220,
      "headline": "J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?",
      "id": 136007863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.",
      "url": "https://finnhub.io/api/news?id=d2a9086031965b4ec27f20fd36ef39587dbf3fb10ab06cf42c7000555d686142"
    }
  },
  {
    "ts": null,
    "headline": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
    "summary": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
    "url": "https://finnhub.io/api/news?id=2264f0b1d781b24dc3e87e7e123c18cc73e712a60f4b74c0d99455fa24e51e6a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752849968,
      "headline": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
      "id": 136008446,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2264f0b1d781b24dc3e87e7e123c18cc73e712a60f4b74c0d99455fa24e51e6a"
    }
  },
  {
    "ts": null,
    "headline": "Microfiltration Membranes Company Evaluation Report 2024-2025 | Merck and Veolia Lead in Microfiltration Market with Strategic Moves",
    "summary": "The Microfiltration Membrane Market Companies Quadrant offers an in-depth analysis of the global microfiltration segment, spotlighting technological advancements and key market trends. It evaluates over 40 companies, highlighting the top 10 as quadrant leaders. Microfiltration, crucial in industries like food, wastewater, and biotechnology, utilizes membranes with pore sizes from 0.1 to 1.0 microns. Increasing demand in Asia-Pacific and the Middle East & Africa, driven by water scarcity and stri",
    "url": "https://finnhub.io/api/news?id=eafe39fbb0f06305f04190749a40c8987dd97091b457c3b00a8ffba44e4d2c79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752847980,
      "headline": "Microfiltration Membranes Company Evaluation Report 2024-2025 | Merck and Veolia Lead in Microfiltration Market with Strategic Moves",
      "id": 136005601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Microfiltration Membrane Market Companies Quadrant offers an in-depth analysis of the global microfiltration segment, spotlighting technological advancements and key market trends. It evaluates over 40 companies, highlighting the top 10 as quadrant leaders. Microfiltration, crucial in industries like food, wastewater, and biotechnology, utilizes membranes with pore sizes from 0.1 to 1.0 microns. Increasing demand in Asia-Pacific and the Middle East & Africa, driven by water scarcity and stri",
      "url": "https://finnhub.io/api/news?id=eafe39fbb0f06305f04190749a40c8987dd97091b457c3b00a8ffba44e4d2c79"
    }
  },
  {
    "ts": null,
    "headline": "3M, American Express share losses contribute to Dow's nearly 250-point fall",
    "summary": "3M, American Express share losses contribute to Dow's nearly 250-point fall",
    "url": "https://finnhub.io/api/news?id=03cc74ec8b2d9793c6b496b549e3010739ccf88069f7361b6127bc9aa6ece718",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752841680,
      "headline": "3M, American Express share losses contribute to Dow's nearly 250-point fall",
      "id": 136041826,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "3M, American Express share losses contribute to Dow's nearly 250-point fall",
      "url": "https://finnhub.io/api/news?id=03cc74ec8b2d9793c6b496b549e3010739ccf88069f7361b6127bc9aa6ece718"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)",
    "summary": "Zoetis leads in animal health with strong EPS growth, key patent-protected drugs, and a rare value entry point. Learn why ZTS stock is upgraded to strong buy.",
    "url": "https://finnhub.io/api/news?id=02e78cf42d29f2da0a70b14a2648f4febbdc001636b97ca5b51a7f0adef87176",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752831011,
      "headline": "Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)",
      "id": 136001411,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1661329207/image_1661329207.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Zoetis leads in animal health with strong EPS growth, key patent-protected drugs, and a rare value entry point. Learn why ZTS stock is upgraded to strong buy.",
      "url": "https://finnhub.io/api/news?id=02e78cf42d29f2da0a70b14a2648f4febbdc001636b97ca5b51a7f0adef87176"
    }
  },
  {
    "ts": null,
    "headline": "Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions",
    "summary": "Discover comprehensive insights with the Livestock Identification Market Companies Quadrant. This analysis evaluates over 100 firms, spotlighting the Top 25 EVA Films leaders, focusing on key players, product innovations, and technological trends. Livestock identification crucially aids in tracking, managing, and ensuring animal health via tagging for purposes like disease control and trade compliance. Market growth is fueled by automation, IoT adoption, and demand for real-time tracking. Key pl",
    "url": "https://finnhub.io/api/news?id=cc2b72363194c70f9a48773db0c04eb610572e21678a2018a71eb20efce784dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752829560,
      "headline": "Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions",
      "id": 136005603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Discover comprehensive insights with the Livestock Identification Market Companies Quadrant. This analysis evaluates over 100 firms, spotlighting the Top 25 EVA Films leaders, focusing on key players, product innovations, and technological trends. Livestock identification crucially aids in tracking, managing, and ensuring animal health via tagging for purposes like disease control and trade compliance. Market growth is fueled by automation, IoT adoption, and demand for real-time tracking. Key pl",
      "url": "https://finnhub.io/api/news?id=cc2b72363194c70f9a48773db0c04eb610572e21678a2018a71eb20efce784dc"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $99 to $98, while keeping a Hold rating on the stock. This small reduction reflects a […]",
    "url": "https://finnhub.io/api/news?id=de4020dab4107c852e9f6a1aaa6bdb76b2570adf0a5c677e489e5094fc1d0250",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752828104,
      "headline": "Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating",
      "id": 136005604,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $99 to $98, while keeping a Hold rating on the stock. This small reduction reflects a […]",
      "url": "https://finnhub.io/api/news?id=de4020dab4107c852e9f6a1aaa6bdb76b2570adf0a5c677e489e5094fc1d0250"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Balanced Fund Q2 2025 Commentary",
    "summary": "Davenport blends dividend discipline, bond yield upside, and contrarian equity picks in DBALX. See how balanced investing still finds value in 2025.",
    "url": "https://finnhub.io/api/news?id=4bdb422e2c4856f5d9f3007eff0a2fbd75d7735fa999ca6fde264ed6f71dd73f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752820500,
      "headline": "The Davenport Balanced Fund Q2 2025 Commentary",
      "id": 136000852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2010464790/image_2010464790.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Davenport blends dividend discipline, bond yield upside, and contrarian equity picks in DBALX. See how balanced investing still finds value in 2025.",
      "url": "https://finnhub.io/api/news?id=4bdb422e2c4856f5d9f3007eff0a2fbd75d7735fa999ca6fde264ed6f71dd73f"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Value & Income Fund Q2 2025 Commentary",
    "summary": "The Davenport Value & Income Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=8fe250ebddd0c5cd485b556d16dd47deb781d90003a77552d4b3581b3cadd026",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752819300,
      "headline": "The Davenport Value & Income Fund Q2 2025 Commentary",
      "id": 136000824,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8fe250ebddd0c5cd485b556d16dd47deb781d90003a77552d4b3581b3cadd026"
    }
  }
]